This project seeks to develop novel vaccines that can be delivered as DNA vaccine components to produce strong neutralizing antibodies. The immunity produced by these vaccines, if successful, can be optimized and then tailored to work in combination with other HIV vaccines to vaccinate at-risk populations and reduce acquisition or severity of HIV.
|Sather, D Noah; Carbonetti, Sara; Malherbe, Delphine C et al. (2014) Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J Virol 88:12968-81|
|Malherbe, Delphine C; Pissani, Franco; Sather, D Noah et al. (2014) Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J Virol 88:12949-67|
|Pissani, Franco; Malherbe, Delphine C; Schuman, Jason T et al. (2014) Improvement of antibody responses by HIV envelope DNA and protein co-immunization. Vaccine 32:507-13|
|Cohen, Kristen; Altfeld, Marcus; Alter, Galit et al. (2014) Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J Virol 88:13310-21|
|Haigwood, Nancy L (2009) Update on animal models for HIV research. Eur J Immunol 39:1994-9|